STOCK TITAN

Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Humacyte (HUMA) submitted an FDA application to add hemodialysis access as a second approved use for its bioengineered blood vessel. The application covers patients with end-stage kidney disease at increased risk that an arteriovenous fistula will not develop enough to be used for dialysis. The FDA approved the vessel as Symvess in December 2024 for extremity vascular trauma.

Three Phase 3 studies support the application. Interim V012 results showed that women who received the vessel gained usable dialysis access more than three months sooner and spent more time without a dialysis catheter over the first year than women who received a fistula. The FDA has 60 days to assess whether the application is complete and acceptable for filing and to set a review timeline. Humacyte requested Priority Review.

Loading...
Loading translation...
6 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointFDA application submitted for a second use of the bioengineered vessel: hemodialysis access
  • Minor pointUsable dialysis access came more than three months sooner with the vessel versus a fistula in women in interim V012 results
  • Minor pointTime without a dialysis catheter was significantly longer over the first year versus a fistula in women in interim V012 results
  • Minor pointCompleted Phase 3 studies V007 and V006 provide additional efficacy and safety data supporting the application
  • Minor pointRegenerative Medicine Advanced Therapy designation granted by the FDA for the vessel's hemodialysis access use
  • Minor pointFast Track designation granted by the FDA for the vessel's hemodialysis access use

Negative

  • Moderate pointHemodialysis access approval remains pending for the proposed use
  • Minor pointFDA acceptance for filing remains pending, with a 60-day period to assess the application and set a review timeline

Key Figures

Supporting Phase 3 studies: 3 studies Time to functional access: More than 3 months sooner FDA filing review period: 60 days
Supporting Phase 3 studies
3 studies
Evidence supporting the sBLA
Time to functional access
More than 3 months sooner
Women receiving ATEV versus AV fistula in the V012 trial
FDA filing review period
60 days
FDA determination of whether the sBLA is complete and acceptable for filing

Historical Context

1 past event · Latest: Nov 11
1 event
  1. Nov 11

    sBLA submission plan

    24h Move
    +0.3%

    The November submission plan is now reported as completed with filing to FDA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

av fistula, regenerative medicine advanced therapy (rmat), fast track designation
3 terms
av fistula medical
"women who received an AV fistula, which is the current standard of care"
An arteriovenous (AV) fistula is a surgically created connection between an artery and a vein that provides a durable, high‑flow access point for long‑term hemodialysis. Think of it like upgrading a garden hose to a wider pipe so large volumes of fluid can be moved reliably; for investors, AV fistulas matter because they influence demand for surgical services, dialysis devices, and related supplies, affect treatment costs and patient outcomes, and can drive reimbursement and regulatory considerations in the renal care market.
regenerative medicine advanced therapy (rmat) regulatory
"received the FDA's first Regenerative Medicine Advanced Therapy (RMAT) designation"
A Regenerative Medicine Advanced Therapy (RMAT) is a U.S. regulatory designation for cell, gene and tissue-based treatments addressing serious or life-threatening conditions that shows early evidence of potential benefit. Think of it as a VIP lane with extra access to the regulator — more interaction, guidance and faster review — which can shorten development time and lower costs, making a program more valuable to investors, though it does not guarantee approval.
fast track designation regulatory
"received the FDA's first Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

–sBLA submission seeks to add arteriovenous access for hemodialysis as second approved indication for the ATEV.

–sBLA supported by results from three Phase 3 studies in hemodialysis access.

–“For too long, patients on dialysis, and women in particular, have had to settle for access options that often do not work well for them. We are excited about the potential of the ATEV to provide a new potential vascular access option for hemodialysis patients in need,” said Laura Niklason, M.D., Ph.D., Co-Founder and Chief Executive Officer of Humacyte.

DURHAM, N.C., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the acellular tissue engineered vessel (ATEV) seeking approval in arteriovenous (AV) access for hemodialysis in patients with end-stage kidney disease (ESKD) who are at an increased risk of AV fistula maturation failure. The sBLA seeks to add hemodialysis access as the second approved indication for the ATEV following the FDA approval of the ATEV under the brand name Symvess® in December 2024 for the extremity vascular trauma indication.

In the recently reported V012 Phase 3 trial, women implanted with the ATEV achieved functional access more than three months sooner and spent significantly more time free of dialysis catheters over the first year than women who received an AV fistula, which is the current standard of care for hemodialysis access across all patients. Women have historically had poorer outcomes with AV fistula procedures, including higher rates of maturation failure, longer times to functional access, and greater reliance on infection-prone catheters. If approved, the ATEV would represent the first new option for patients needing alternative hemodialysis access options in decades. The proposed utilization of the ATEV in dialysis access would provide the near-term availability of a ready-to-use biologic conduit that has been observed to perform predictably in patients with small vessel anatomy, diabetes, obesity, or other factors that complicate AV fistula maturation. The ATEV represents a new option for many of the nearly 500,000 Americans currently dependent on hemodialysis for survival, offering a potentially safer and more reliable path to hemodialysis access.

“Submission of our sBLA for ATEV in hemodialysis access is a significant milestone for Humacyte and an important step toward giving patients on dialysis a potential new access option,” said Laura Niklason, M.D., Ph.D., Co-Founder and Chief Executive Officer of Humacyte. “I want to thank the patients and medical professionals who participated in our three Phase 3 clinical studies, and our Humacyte team for their tremendous effort and dedication in completing the sBLA submission. We believe the ATEV has the potential to address a significant unmet need for patients who depend on hemodialysis, and we look forward to working closely with the FDA during its review. For too long, patients on dialysis, and women in particular, have had to settle for access options that often do not work well for them, leaving many reliant on infection-prone catheters. We are excited about the potential of the ATEV to provide a new potential vascular access option for patients in need.”

The FDA has a 60-day review period to determine whether the sBLA is complete and acceptable for filing, as well as to set a timeline for their review. Humacyte has requested Priority Review of the application. The ATEV for AV access in hemodialysis received the FDA's first Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

The sBLA submission follows the presentation of breakthrough top-line interim results from the V012 Phase 3 trial in female dialysis access patients at the American Society of Nephrology’s (ASN) Kidney Week 2026 in October 2026 and at the Society of Vascular Surgery’s (SVS) Vascular Annual Meeting (VAM) in June 2026. Results from the V012 study showed that the ATEV outperformed autologous arteriovenous (AV) fistula, the current standard of care for patients on dialysis. The sBLA is also supported by efficacy and safety results from the comprehensive V007 and V006 studies, two previously completed Phase 3 studies of the ATEV in male and female dialysis access patients.

“This submission brings us one step closer to our goal of providing a new vascular access option for patients on hemodialysis,” Niklason said. “We look forward to the FDA’s review and remain focused on the opportunity to make a meaningful difference for patients in need of vascular access.”

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and Form 10-Q for the quarter ended September 30, 2026, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What use is Humacyte seeking FDA approval for with its bioengineered vessel?

Humacyte is seeking approval for arteriovenous access for hemodialysis in patients with end-stage kidney disease who are at increased risk that a fistula will not mature enough for dialysis. This would be the vessel's second approved use.

What did Humacyte's Phase 3 V012 hemodialysis access trial show in women?

Interim V012 results showed that women who received Humacyte's vessel gained usable dialysis access more than three months sooner than women who received an arteriovenous fistula. They also spent significantly more time without a dialysis catheter over the first year.

Which other Phase 3 studies support Humacyte's FDA application for hemodialysis access?

The completed V007 and V006 Phase 3 studies also support the application with efficacy and safety results from male and female dialysis access patients.

Keep reading